Invesco Ltd. Arrowhead Pharmaceuticals, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 242,875 shares of ARWR stock, worth $5.41 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

242,875

Previous 259,556 6.43%

Holding current value

$5.41 Million

Previous $6.75 Million 30.29%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$19.36 - $29.54 $322,944 - $492,756	-16,681 Reduced 6.43%	242,875 $4.7 Million
Q2 2024 Aug 13, 2024	BUY	$21.87 - $28.24 $116,260 - $150,123	5,316 Added 2.09%	259,556 $6.75 Million
Q1 2024 May 14, 2024	SELL	$27.21 - $39.48 $55.8 Million - $81 Million	-2,052,068 Reduced 88.98%	254,240 $7.27 Million
Q4 2023 Feb 12, 2024	SELL	$21.2 - $31.03 $2.9 Million - $4.24 Million	-136,730 Reduced 5.6%	2,306,308 $70.6 Million
Q3 2023 Nov 13, 2023	BUY	$26.2 - $36.08 $5.62 Million - $7.74 Million	214,618 Added 9.63%	2,443,038 $65.6 Million
Q2 2023 Aug 11, 2023	BUY	$25.16 - $41.38 $1.2 Million - $1.97 Million	47,627 Added 2.18%	2,228,420 $79.5 Million
Q1 2023 May 12, 2023	SELL	$23.68 - $38.51 $85,461 - $138,982	-3,609 Reduced 0.17%	2,180,793 $55.4 Million
Q4 2022 Feb 13, 2023	SELL	$28.0 - $40.56 $879,984 - $1.27 Million	-31,428 Reduced 1.42%	2,184,402 $88.6 Million
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $431,264 - $703,152	14,555 Added 0.66%	2,215,830 $73.2 Million
Q2 2022 Aug 15, 2022	SELL	$27.79 - $50.61 $3.69 Million - $6.72 Million	-132,799 Reduced 5.69%	2,201,275 $77.5 Million
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $1.13 Million - $1.99 Million	28,433 Added 1.23%	2,334,074 $107 Million
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $453,218 - $643,743	-7,802 Reduced 0.34%	2,305,641 $153 Million
Q3 2021 Nov 15, 2021	SELL	$58.38 - $84.96 $11.3 Million - $16.4 Million	-193,073 Reduced 7.7%	2,313,443 $144 Million
Q2 2021 Aug 17, 2021	SELL	$62.15 - $90.32 $55 Million - $79.9 Million	-884,393 Reduced 26.08%	2,506,516 $208 Million
Q1 2021 May 17, 2021	BUY	$61.35 - $90.47 $8.1 Million - $11.9 Million	132,044 Added 4.05%	3,390,909 $225 Million
Q4 2020 Feb 16, 2021	SELL	$43.82 - $85.37 $1.07 Million - $2.08 Million	-24,388 Reduced 0.74%	3,258,865 $250 Million
Q3 2020 Nov 16, 2020	SELL	$33.21 - $51.27 $1.63 Million - $2.51 Million	-48,941 Reduced 1.47%	3,283,253 $141 Million
Q2 2020 Aug 14, 2020	BUY	$26.12 - $43.27 $4.23 Million - $7.01 Million	162,054 Added 5.11%	3,332,194 $144 Million
Q1 2020 May 15, 2020	SELL	$20.56 - $63.12 $2.47 Million - $7.59 Million	-120,219 Reduced 3.65%	3,170,140 $91.2 Million
Q4 2019 Feb 14, 2020	SELL	$28.14 - $73.01 $44.3 Million - $115 Million	-1,575,279 Reduced 32.38%	3,290,359 $209 Million
Q3 2019 Nov 14, 2019	BUY	$26.26 - $34.86 $1.18 Million - $1.57 Million	45,031 Added 0.93%	4,865,638 $137 Million
Q2 2019 Aug 14, 2019	BUY	$17.43 - $28.82 $71.1 Million - $118 Million	4,079,523 Added 550.48%	4,820,607 $128 Million
Q1 2019 May 15, 2019	BUY	$12.05 - $20.18 $4.7 Million - $7.87 Million	389,771 Added 110.95%	741,084 $13.6 Million
Q4 2018 Feb 14, 2019	BUY	$10.74 - $19.7 $3.77 Million - $6.92 Million	351,313 New	351,313 $4.36 Million

Others Institutions Holding ARWR

# of Institutions

295

Shares Held

91.1M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.36B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account